Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
Hans-Peter Beck, Rahel Wampfler, Nick Carter, Gavin Koh, Lyda Osorio, Ronnatrai Rueangweerayut, Srivcha Krudsood, Marcus V Lacerda, Alejandro Llanos-Cuentas, Stephan Duparc, Justin P Rubio, Justin A Green, Hans-Peter Beck, Rahel Wampfler, Nick Carter, Gavin Koh, Lyda Osorio, Ronnatrai Rueangweerayut, Srivcha Krudsood, Marcus V Lacerda, Alejandro Llanos-Cuentas, Stephan Duparc, Justin P Rubio, Justin A Green
Abstract
Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse.
Clinical trials registration: NCT01376167.
Keywords: Plasmodium vivax; antihypnozoite; efficacy; genotyping; tafenoquine.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Battle KE, Gething PW, Elyazar IR et al. . The global public health significance of Plasmodium vivax. Adv Parasitol 2012; 80:1–111.
- Campo B, Vandal O, Wesche DL, Burrows JN. Killing the hypnozoite—drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health 2015; 109:107–22.
- Koepfli C, Mueller I, Marfurt J et al. . Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 2009; 199:1074–80.
- Koepfli C, Ross A, Kiniboro B et al. . Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis 2011; 5:e1424.
- Lin JT, Hathaway NJ, Saunders DL et al. . Using amplicon deep sequencing to detect genetic signatures of Plasmodium vivax relapse. J Infect Dis 2015; 212:999–1008.
- Llanos-Cuentas A, Lacerda MV, Rueangweerayut R et al. . Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049–58.
- Mendes C, Dias F, Figueiredo J et al. . Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis 2011; 5:e1192.
- Ord RL, Tami A, Sutherland CJ. ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency. PLoS One 2008; 3:e3366.
- Bennett JW, Pybus BS, Yadava A et al. . Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013; 369:1381–2.
- Batista CL, Barbosa S, Da Silva Bastos M, Viana SA, Ferreira MU. Genetic diversity of Plasmodium vivax over time and space: a community-based study in rural Amazonia. Parasitology 2014:1–11.
- Thanapongpichat S, McGready R, Luxemburger C et al. . Microsatellite genotyping of Plasmodium vivax infections and their relapses in pregnant and non-pregnant patients on the Thai-Myanmar border. Malar J 2013; 12:275.
- Van den Eede P, Van der Auwera G, Delgado C et al. . Multilocus genotyping reveals high heterogeneity and strong local population structure of the Plasmodium vivax population in the Peruvian Amazon. Malar J 2010; 9:151.
- Dhangadamajhi G, Rout BK, Kar SK, Ranjit MR. Genetic diversity of Plasmodium vivax in a hyperendemic area predominated by Plasmodium falciparum; a preliminary study. Trop Biomed 2010; 27:578–84.
- Betuela I, Rosanas-Urgell A, Kiniboro B et al. . Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis 2012; 206:1771–80.
Source: PubMed